Literature DB >> 23677023

A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.

Jennifer E Balkus1, Barbra A Richardson, Vernon Mochache, Vrasha Chohan, Jeannie D Chan, Linnet Masese, Juma Shafi, Jeanne Marrazzo, Carey Farquhar, R Scott McClelland.   

Abstract

BACKGROUND: This analysis compared the frequency of persistent Trichomonas vaginalis (TV) among HIV-seropositive and HIV-seronegative women.
METHODS: Data were obtained from women enrolled in an open cohort study of sex workers in Kenya. Participants were examined monthly, and those diagnosed as having TV by saline microscopy were treated with single-dose 2 g oral metronidazole. All women on antiretroviral therapy (ART) used nevirapine-based regimens. Generalized estimating equations with a logit link were used to compare the frequency of persistent TV (defined as the presence of motile trichomonads by saline microscopy at the next examination visit within 60 days) by HIV status.
RESULTS: Three-hundred sixty participants contributed 570 infections to the analysis (282 HIV-seropositive and 288 HIV-seronegative). There were 42 (15%) persistent infections among HIV-seropositive participants versus 35 (12%) among HIV-seronegative participants (adjusted odds ratio, 1.14; 95% confidence interval [CI], 0.70-1.87). Persistent TV was highest among HIV-seropositive women using ART (21/64 [33%]) compared with HIV-seropositive women not using ART (21/217 [10%]). Concurrent bacterial vaginosis (BV) at TV diagnosis was associated with an increased likelihood of persistent TV (adjusted odds ratio, 1.90; 95% confidence interval, 1.16-3.09).
CONCLUSIONS: The frequency of persistent TV infection after treatment with single-dose 2 g oral metronidazole was similar by HIV status. Alternative regimens including multiday antibiotic treatment may be necessary to improve cure rates for women using nevirapine-based ART and women with TV and concurrent BV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23677023      PMCID: PMC3676301          DOI: 10.1097/OLQ.0b013e31828fce34

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  26 in total

1.  Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women.

Authors:  L M Niccolai; J J Kopicko; A Kassie; H Petros; R A Clark; P Kissinger
Journal:  Sex Transm Dis       Date:  2000-05       Impact factor: 2.830

2.  The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1.

Authors:  C C Wang; R S McClelland; M Reilly; J Overbaugh; S R Emery; K Mandaliya; B Chohan; J Ndinya-Achola; J Bwayo; J K Kreiss
Journal:  J Infect Dis       Date:  2001-02-28       Impact factor: 5.226

3.  Possible alteration of metronidazole metabolism by phenobarbital.

Authors:  P B Mead; M Gibson; J J Schentag; J A Ziemniak
Journal:  N Engl J Med       Date:  1982-06-17       Impact factor: 91.245

4.  Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection.

Authors:  Susan Cu-Uvin; Hyejin Ko; Denise J Jamieson; Joseph W Hogan; Paula Schuman; Jean Anderson; Robert S Klein
Journal:  Clin Infect Dis       Date:  2002-04-22       Impact factor: 9.079

5.  Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition.

Authors:  H L Martin; B A Richardson; P M Nyange; L Lavreys; S L Hillier; B Chohan; K Mandaliya; J O Ndinya-Achola; J Bwayo; J Kreiss
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

Review 6.  Summary of information on human CYP enzymes: human P450 metabolism data.

Authors:  Slobodan Rendic
Journal:  Drug Metab Rev       Date:  2002 Feb-May       Impact factor: 4.518

7.  Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study.

Authors:  J M Baeten; P M Nyange; B A Richardson; L Lavreys; B Chohan; H L Martin; K Mandaliya; J O Ndinya-Achola; J J Bwayo; J K Kreiss
Journal:  Am J Obstet Gynecol       Date:  2001-08       Impact factor: 8.661

8.  Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations.

Authors:  R Amsel; P A Totten; C A Spiegel; K C Chen; D Eschenbach; K K Holmes
Journal:  Am J Med       Date:  1983-01       Impact factor: 4.965

9.  Influence of HIV-1 coinfection on effective management of abnormal vaginal discharge.

Authors:  Prashini Moodley; David Wilkinson; Cathy Connolly; A Willem Sturm
Journal:  Sex Transm Dis       Date:  2003-01       Impact factor: 2.830

10.  Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity?

Authors:  Manya Magnus; Rebecca Clark; Leann Myers; Thomas Farley; Patricia J Kissinger
Journal:  Sex Transm Dis       Date:  2003-11       Impact factor: 2.830

View more
  12 in total

1.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

2.  Epidemiology and treatment of trichomoniasis.

Authors:  Patricia Kissinger
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

3.  The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA.

Authors:  Maria L Alcaide; Daniel J Feaster; Rui Duan; Stephanie Cohen; Chanelle Diaz; Jose G Castro; Matthew R Golden; Sarah Henn; Grant N Colfax; Lisa R Metsch
Journal:  Sex Transm Infect       Date:  2015-06-12       Impact factor: 3.519

4.  Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 20.999

Review 5.  Integrating prevention interventions for people living with HIV into care and treatment programs: a systematic review of the evidence.

Authors:  Amy Medley; Pamela Bachanas; Michael Grillo; Nina Hasen; Ugochukwu Amanyeiwe
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

Review 6.  Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation.

Authors:  Catriona S Bradshaw; Jack D Sobel
Journal:  J Infect Dis       Date:  2016-08-15       Impact factor: 5.226

7.  The influence of ART on the treatment of Trichomonas vaginalis among HIV-infected women.

Authors:  Alys Adamski; Rebecca A Clark; Leandro Mena; Harold Henderson; Judy Levison; Norine Schmidt; Hirut T Gebrekristos; David H Martin; Patricia Kissinger
Journal:  Clin Infect Dis       Date:  2014-06-09       Impact factor: 9.079

Review 8.  A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.

Authors:  Elissa Meites; Charlotte A Gaydos; Marcia M Hobbs; Patricia Kissinger; Paul Nyirjesy; Jane R Schwebke; W Evan Secor; Jack D Sobel; Kimberly A Workowski
Journal:  Clin Infect Dis       Date:  2015-12-15       Impact factor: 9.079

Review 9.  Antiretroviral therapy uptake, attrition, adherence and outcomes among HIV-infected female sex workers: a systematic review and meta-analysis.

Authors:  Elisa Mountain; Sharmistha Mishra; Peter Vickerman; Michael Pickles; Charles Gilks; Marie-Claude Boily
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

Review 10.  Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues.

Authors:  Patricia Kissinger
Journal:  BMC Infect Dis       Date:  2015-08-05       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.